These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 19171914

  • 1. Developing countries need better antiretroviral drugs.
    Mykén N, Sundbeck B, Mpumilwa G, Andersson R.
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(1):23-4. PubMed ID: 19171914
    [No Abstract] [Full Text] [Related]

  • 2. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
    Tin EE, Bowonwatanuwong C, Desakorn V, Wilairatana P, Krudsood S, Pitisuttithum P.
    Southeast Asian J Trop Med Public Health; 2005 Mar; 36(2):362-9. PubMed ID: 15916042
    [Abstract] [Full Text] [Related]

  • 3. Outcomes of a remote, decentralized health center-based HIV/AIDS antiretroviral program in Zambia, 2003 to 2007.
    Elema R, Mills C, Yun O, Lokuge K, Ssonko C, Nyirongo N, Mtonga V, Zulu H, Tu D, Verputten M, O'Brien DP.
    J Int Assoc Physicians AIDS Care (Chic); 2009 Mar; 8(1):60-7. PubMed ID: 19211930
    [Abstract] [Full Text] [Related]

  • 4. [Clinical safety of a generic fixed-dose combination of stavudine/lamivudine/névirapine (Triomune). Study of 297 cases in Togo].
    Mouhari-Touré A, Saka B, Kombat K, Tchangaï-Walla K, Pitche P.
    Bull Soc Pathol Exot; 2008 Dec; 101(5):404-6. PubMed ID: 19192611
    [Abstract] [Full Text] [Related]

  • 5. Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine.
    Laurent C, Kouanfack C, Koulla-Shiro S, Njoume M, Nkene YM, Ciaffi L, Brulet C, Peytavin G, Vergne L, Calmy A, Mpoudi-Ngolé E, Delaporte E.
    AIDS; 2007 Mar 30; 21(6):768-71. PubMed ID: 17413701
    [Abstract] [Full Text] [Related]

  • 6. Severe ototoxicity in a health care worker who received postexposure prophylaxis with stavudine, lamivudine, and nevirapine after occupational exposure to HIV.
    Rey D, L'Héritier A, Lang JM.
    Clin Infect Dis; 2002 Feb 01; 34(3):418-9. PubMed ID: 11774091
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi.
    van Oosterhout JJ, Bodasing N, Kumwenda JJ, Nyirenda C, Mallewa J, Cleary PR, de Baar MP, Schuurman R, Burger DM, Zijlstra EE.
    Trop Med Int Health; 2005 May 01; 10(5):464-70. PubMed ID: 15860093
    [Abstract] [Full Text] [Related]

  • 8. Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand.
    Tsuchiya N, Pathipvanich P, Yasuda T, Mukoyama Y, Rojanawiwat A, Matsubayashi T, Saeng-aroon S, Auwanit W, Matsuyama A, Sawanpanyalert P, Ariyoshi K.
    Southeast Asian J Trop Med Public Health; 2009 Jan 01; 40(1):71-82. PubMed ID: 19323037
    [Abstract] [Full Text] [Related]

  • 9. Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.
    Laurent C, Bourgeois A, Mpoudi-Ngolé E, Ciaffi L, Kouanfack C, Mougnutou R, Nkoué N, Calmy A, Koulla-Shiro S, Delaporte E.
    AIDS Res Hum Retroviruses; 2008 Mar 01; 24(3):393-9. PubMed ID: 18327976
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients.
    Kiertiburanakul S, Khongnorasat S, Rattanasiri S, Sungkanuparph S.
    J Med Assoc Thai; 2007 Feb 01; 90(2):237-43. PubMed ID: 17375626
    [Abstract] [Full Text] [Related]

  • 11. Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting.
    Shalit P, Farrell P, Lindgren P.
    AIDS; 2001 Apr 13; 15(6):804-5. PubMed ID: 11371699
    [No Abstract] [Full Text] [Related]

  • 12. Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
    Cournil A, Coudray M, Kouanfack C, Essomba CN, Tonfack CA, Biwolé-Sida M, Delaporte E, Bork K, Laurent C.
    Antivir Ther; 2010 Apr 13; 15(7):1039-43. PubMed ID: 21041920
    [Abstract] [Full Text] [Related]

  • 13. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
    Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L, Médecins Sans Frontieres.
    AIDS; 2006 May 12; 20(8):1163-9. PubMed ID: 16691068
    [Abstract] [Full Text] [Related]

  • 14. Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH, Hassink EA, van Eck-Smit BL, Borleffs JC, Lange JM, Reiss P.
    HIV Clin Trials; 2007 May 12; 8(5):337-44. PubMed ID: 17956835
    [Abstract] [Full Text] [Related]

  • 15. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda).
    Songa PM, Castelnuovo B, Mugasha EB, Ocama P, Kambugu A.
    Clin Infect Dis; 2007 Aug 15; 45(4):514-7. PubMed ID: 17638205
    [Abstract] [Full Text] [Related]

  • 16. Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon.
    Bourgeois A, Laurent C, Mougnutou R, Nkoué N, Lactuock B, Ciaffi L, Liégeois F, Andrieux-Meyer I, Zekeng L, Calmy A, Mpoudi-Ngolé E, Delaporte E.
    Antivir Ther; 2005 Aug 15; 10(2):335-41. PubMed ID: 15865228
    [Abstract] [Full Text] [Related]

  • 17. [A short-term trial of Didanosine, stavudine, and nevirapine combination therapy for human immunodeficiency virus infection].
    Zheng YH, Yang X, Chang WH.
    Hunan Yi Ke Da Xue Xue Bao; 2003 Aug 15; 28(4):390. PubMed ID: 14653126
    [No Abstract] [Full Text] [Related]

  • 18. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda.
    van Griensven J, De Naeyer L, Mushi T, Ubarijoro S, Gashumba D, Gazille C, Zachariah R.
    Trans R Soc Trop Med Hyg; 2007 Aug 15; 101(8):793-8. PubMed ID: 17467756
    [Abstract] [Full Text] [Related]

  • 19. Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense.
    Kitkungvan D, Apisarnthanarak A, Laowansiri P, Mundy LM.
    HIV Med; 2008 Oct 15; 9(8):636-41. PubMed ID: 18643857
    [Abstract] [Full Text] [Related]

  • 20. Effect of highly active antiretroviral therapy on CD4 count and weight in AIDS patients seen at the UITH, Ilorin.
    Olawumi HO, Olatunji PO, Salami AK, Odeigah L, Iseniyi JO.
    Niger J Clin Pract; 2008 Dec 15; 11(4):312-5. PubMed ID: 19320401
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.